NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で75.54%の成長率を示しています。
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 79.91Mに達しています。
割安
同社の最新のPEは-12.43で、過去3年間の水準と比較して安値圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は29.13M株で、前四半期比で3.88%減少しています。
バンガードが保有
スター投資家バンガードは本銘柄を1.37M株保有しています。
市場活動が低調
同社への投資家の関心は低下しており、20日間の売買回転率は0.28です。